Rhythm Pharmaceuticals, Inc. (RYTM) stock analysis
In our weekly check, Rhythm Pharmaceuticals, Inc. is graded D (A to F). Of 23 checks on debt, profit, cash flow and trend: 10 pass, warnings: 3, red flags: 10.
About Rhythm Pharmaceuticals, Inc.
Rhythm Pharmaceuticals, Inc. is a Healthcare company (Biotechnology) based in the United States, listed on NASDAQ as RYTM.
What our checks show for RYTM
Red flags
- The company has an operating loss, so it does not cover the interest bill: interest is paid from cash or new debt.
- Earnings per share fell 6.2% a year over the last 3 years.
- The company is losing money: the net margin is -69%.
- Free cash flow is negative (-41.5% of revenue): the business spends more cash than it brings in.
- Rhythm Pharmaceuticals, Inc. pays a dividend while losing money: it is funded from reserves or debt.
- The price swings a lot: 51.3% annual volatility. Expect large ups and downs.
- The stock has fallen as much as 92% from a peak. Would you have held through that?
- Beta 2.13: the stock usually moves more than the market, both up and down.
- Return on capital (ROCE) is zero or negative: the business does not earn on the money put into it.
- Free cash flow is negative, so no cash is left over to cover pay in shares.
Warning signs
- Operating cash flow is negative while the company reports a profit: the profit does not arrive as cash.
- Analysts expect earnings per share to shrink about 21.8% a year.
- The share count grew by 12.7% in 2 years: each shareholder owns a smaller slice.
Strengths
- Debt is low: 0.02x equity.
- The net margin rose by 2138 points over 5 years, to -69%.
- The gross margin is 88.2% and has risen by 7.2 points: pricing power is holding.
- Analysts expect revenue to grow about 65.2% a year over the next years.
- Analysts expect the net margin to improve by 84.2 points from today's -69%.
- Revenue grew 128% a year over the last 3 years.
Similar companies
CYTK · ABVX · AXSM · PTGX · TWST · ORKA
Questions
What grade does Rhythm Pharmaceuticals, Inc. (RYTM) have?
In our weekly check, Rhythm Pharmaceuticals, Inc. is graded D (A to F). Of 23 checks on debt, profit, cash flow and trend: 10 pass, warnings: 3, red flags: 10. The grade is a risk check, not a buy or sell recommendation.
What are the main risks of RYTM stock?
This week's biggest flags for Rhythm Pharmaceuticals, Inc.: Weak interest cover, Weak EPS growth, Thin margins. In total 13 of 23 checks show a warning or a red flag.
What does Rhythm Pharmaceuticals, Inc. do?
Rhythm Pharmaceuticals, Inc. is a Healthcare company (Biotechnology) based in the United States, listed on NASDAQ as RYTM.
The grade is a risk check, not a price forecast, and not investment advice. In our 10-year test (S&P 500, 2016-2026), stocks we graded A or B fell more than 30% 2-3 times less often than D or F, without a lower average return.
Updated 2026-11-14
Open the full analysis